HOME > 研究活動 > 2020（令和2）年度

研究業績：2020（令和2）年度

論文

A 欧文
A-a
  1. Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H: Efficacy of Tadalafil Therapy and Changes inOxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder. Low Urin TractSymptoms 12(1): 47-53, 2020. doi: 10.1111/luts.12283. (IF: 1.592) ＊
  2. Tagami A, Tomita M, Adachi S, Tsuda K, Yamada S, Chiba K, Okazaki N, Yonekura A, Tsujimoto R, Kajiyama S,Matsubayashi S, Miyamoto T, Mochizuki Y, Ohba K, Osaki M: Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. JBone Miner Metab 38(1): 78-85, 2020. doi: 10.1007/s00774-019-01028-6. (IF: 2.626) ＊
  3. Kawano H, Ando T, Shida Y, Niino D, Maemura K, Kawai K: Isolated left adrenal medullary hyperplasia. J Cardiol Cases21(1): 16-19, 2020. doi: 10.1016/j.jccase.2019.08.018. (IF: 0.528)
  4. Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E,Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, Suzuki K : Diagnostic Impacts of Clinical Laboratory Based p2PSAIndexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigenbelow 10 ng/ml. J Urol 203(1): 83-91, 2020. doi: 10.1097/JU.0000000000000495. (IF: 1.18) ＊
  5. Shida Y, Hakariya T, Miyata Y, Sakai H: Three cases of brain metastasis from castration-resistant prostate cancer. Clin.Case Rep. 8(1): 96-99, 2020. doi: 10.1002/ccr3.2587. (IF: 0.532) ＊
  6. Kitamura M, Tateishi Y, Sato S, Ota Y, Muta K, Uramatsu T, Izumo T, Mochizuki Y, Harada T, Funakoshi S, Matsuo T,Tsujino A, Sakai H, Mukae H, Nishino T: Lower serum calcium and pre-onset blood pressure elevation in cerebralhemorrhage patients undergoing hemodialysis. Clin. Exp. Nephrol. 24(5): 465-473, 2020. doi: 10.1007/s10157-020-01846-3. (IF: 2.801) ＊
  7. Wang M, Hiraki R, Nakamura N, Hayama T, Yasuda T, Miyata Y, Sakai H, Nakashima MN, Nakashima M, Ohyama K:Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography withUltraviolet Detection. J. Chromatogr. Sci. : 2020. doi: 10.1093/chromsci/bmaa020. (IF: 1.618) ＊
  8. Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M,Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N,Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y,Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, NishiyamaH, Shinohara N: Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.Cancer Sci. 111(7): 2460-2471, 2020. doi: 10.1111/cas.14449. (IF: 6.716) ＊
  9. Mukae Y, Miyata Y, Nakamura Y, Araki K, Otsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathologicalroles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growthfactor-A and programmed death ligand 1. Oncol. Lett. 20(1): 135-144, 2020. doi: 10.3892/ol.2020.11540. (IF: 2.967) 〇＊
  10. Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Coler-Reilly A,Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, TaylorGP, YamanoY: Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spasticparaparesis. Orphanet J. Rare Dis. 15(1): 175, 2020. doi: 10.1186/s13023-020-01451-3. (IF: 4.123) ＊
  11. Tsuji K, Kitamura M, Muta K, Mochizuki Y, Mori T,Sohara E, Uchida S, Sakai H, Mukae H, Nishino T: Transplantation ofa kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report. BMCNephrol. 21(1): 282, 2020. doi: 10.1186/s12882-020-01940-4. (IF: 2.388) ＊
  12. Miyata Y, Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H:Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy byregulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.Mol. Clin. Oncol. 13(4): 29, 2020. doi: 10.3892/mco.2020.2099. (IF: 1.63) ＊
  13. Yuno Y, Miyata M, Matsuo T, Mukae Y, Otsubo A, Mistunari K, Ohba K,Suda T,Saito S, Sakai H: Relationship BetweenStage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.Anticancer Res. 40(10): 5567-5575, 2020. doi: 10.21873/anticanres.14569. (IF: 2.48) 〇＊
  14. Yuno Y, Miyata Y, Mukae Y, Otsubo A, Mitsunari K, Matsuo T, Ohba K, Sakai H: Mechanisms Underlying the Inhibitionof Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and theCorrelation between Macrophage Colony Stimulating Factor and Inflammatory Mediators. Med Sci (Basel) 8(4): 43, 2020.doi: 10.3390/medsci8040043. (IF: 3.738)
  15. Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly HasProtective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: ARandomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2. Medicines (Basel) 7(11):71, 2020. doi: 10.3390/medicines7110071. (IF: 1.889)
  16. Eguchi S, Hidaka M, Natsuda K, Hara T, Kugiyama T, Hamada T, Tanaka T, Ono S, Adachi T,Kanetaka K,Soyama A,Mochizuki Y, Sakai H: Simultaneous Deceased Donor Liver and Kidney Transplantation in a Human ImmunodeficiencyVirus/Hepatitis C Virus -Coinfected Patient With Hemophilia in Japan: A Case Report. Transplant. Proc. 52(9): 2786-2789,2020. doi: 10.1016/j.transproceed.2020.05.005. (IF: 1.066) ＊
  17. Araki K, Miyata Y, Ohba K, Nakamura Y,Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly HasProtective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: ARandomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2. Medicines (Basel) 7(11): 71, 2020. doi:10.3390/medicines7110071. (IF: 1.889)
  18. Miyata Y,Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H:Erratum: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapyby regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinicaltrial. Mol. Clin. Oncol. 13(6): 78, 2020. doi: 10.3892/mco.2020.2148. (IF: 1.63) ＊
A-b
  1. Mastuo T, Miyata Y, Yuno T, Mukae Y, Otsubo A, Mitsunari K, Ohba K, Sakai H: Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer. Molecules 25(3): 575, 2020. doi:10.3390/molecules25030575. (IF: 4.148) ＊
  2. Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathological and PharmacologicalRoles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds,Natural Products, and Photosensitizers. Molecules 25(22): 5252, 2020. doi: 10.3390/molecules25225252. (IF: 4.411) ＊
  3. Miyata Y, Matsuo T, Ohba K, Mitsunari K, Mukae Y, Otsubo A, Harada J, Matsuda T, Kondo T, Sakai H: Present Status,Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer. Cancers12(12): 2020. doi: 10.3390/cancers12123776. (IF: 6.639) ＊
A-e-1
  1. Miyata Y, Ohba K, Matsuo T, Mitsunari K, Sakai H: A randomized, double-blinded clinical trial of royal jelly intake foranticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors. J.Clin. Oncol. 38(6): 2020. (IF: 44.544) ＊
  2. Matsuo T,Miyata Y,Mitsunari K,Ohba K, Sakai H: Long-term outcomes of patients with locally advanced bladder cancerthat underwent intra-arterial chemotherapy with/without radiotherapy for organ preservation. J. Clin. Oncol. 38(6): 2020.(IF: 44.544) ＊
  3. Ohtsubo A, Oshiro T, Kimura R, Miyazato M, Matsuo T, Miyata Y, Sakai H: OXIDATIVE STRESS INDUCESDETRUSOR UNDERACTIVITY AND URETHRAL DYSFUNCTION IN AGING RATS. J. Clin. Oncol. 203: E533-E534,2020. (IF: 44.544) ＊
  4. Ohtsubo A, Matsuo T, Mukae Y, Mitsunari K, Ohba K, Miyata Y, Sakai H: PREOPERATIVE NUTRITIONAL STATUSOF TRANSURETHRAL LITHOTRIPSY AFFECTS DEVELOPMENT OF POSTOPERATIVE SYSTEMICINFLAMMATORY RESPONSE SYNDROME. J. Clin. Oncol. 203: E275, 2020. (IF: 44.544) ＊
  5. Mukae Y, Miyata Y, Ohtsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: KIBRA AND PHOSPHORYLATEDLATS-2 ARE NEGATIVELY ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND ARE PROGNOSTICINDICATORS IN PATIENTS WITH RENAL CELL CARCINOMA. J. Clin. Oncol. 203: E113-E114, 2020. (IF: 44.544)＊
  6. Miyata Y, Yuno T, Mukae Y, Mitsunari K, Matsuo T, Ohba K, Sakai H, Otsubo A: INHIBITION OF E-TYPEPROSTANOID RECEPTOR 1 INHIBITS THE MALIGNANT POTENTIAL OF PROSTATE CANCER CELLS IN ANANIMAL MODEL. J. Clin. Oncol. 203: E560, 2020. (IF: 44.544) ＊
B 邦文
B-a
  1. 宮田康好,松尾朋博,光成健輔,大庭康司郎,酒井英樹: 進行性尿路がんの2次治療における地域の医療・福祉サービスとの診療連携の有用性:生命予後やQoLへの影響. 泌尿器科紀要 66(4): 107-113, 2020.
  2. 望月 保志,大庭 康司郎,宮田 康好,酒井 英樹,大野 慎一郎,日高 匡章,江口 晋8: 複合臓器移植の経験と泌尿器科医の役割. 西日本泌尿器科 82(3): 350-356, 2020.
  3. 望月 保志,計屋 知彰,大庭 康司郎,宮田 康好,酒井 英樹: 【副甲状腺外科治療を極める】二次性副甲状腺機能亢進症の治療変遷と外科治療. 日本内分泌外科学会雑誌 37(4): 237-241, 2020.
  4. 計屋 知彰,酒井 英樹: 【副腎皮質疾患】長崎大学における副腎皮質癌の診療の実際 泌尿器科の立場から. 日本内分泌外科学会雑誌 37(4): 276-281, 2020.
B-b
  1. 酒井英樹1: 【前立腺がんの過剰診断・過剰治療の解決策】日本人の前立腺がん　罹患率と死亡率の動向. 泌尿器科 11(1): 1-6, 2020.
  2. 計屋 知彰: 【前立腺癌治療の合併症・副作用マネージメント】骨修飾薬 投与前の注意と投与中の副作用対策.Prostate Journal 7(1): 76-79, 2020.
  3. 酒井英樹4: 【泌尿器科診療の最新スタンダード-平成の常識は令和の非常識】内分泌疾患　原発性アルドステロン症. 臨床泌尿器科 74(4): 190-193, 2020.
  4. 松尾 朋博,大坪 亜紗斗,迎 祐太,湯野 努,光成 健輔,大庭 康司郎,宮田 康好,酒井 英樹: 【夜間頻尿治療の最先端】夜間頻尿の治療 行動療法に関する最前線. 日本排尿機能学会誌 30(2): 107-113, 2020.
  5. 松尾朋博,宮田康好,酒井英樹: これが最新版!過活動膀胱のトリセツ〈過活動膀胱の治療と問題点〉行動療法. 臨床泌尿器科 74(8): 570-574, 2020.
  6. 計屋 知彰,酒井 英樹: 【前立腺癌の薬物療法:ホルモン感受性癌から去勢抵抗性癌まで】新規ホルモン治療薬.Prostate Journal 7(2): 171-175, 2020.
  7. 志田洋平, 酒井英樹: 【前立腺肥大症の新しい外科的治療の選択肢】前立腺肥大症の下部尿路症状に対する経尿道的水蒸気治療. 泌尿器科 12(4): 396-400, 2020.
  8. 計屋 知彰: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器科専門領域の最新情報(vol.5) 副腎腫瘍 褐色細胞腫の診断と治療. Uro-Lo: 泌尿器Care & Cure 25(6): 864-867, 2020.
  9. 中村裕子, 岡田みずほ, 小渕美樹子, 志田洋平, 酒井英樹: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器科専門領域の最新情報(vol.5)　副腎腫瘍　副腎腫瘍手術患者の看護　病棟看護師の役割. Uro-Lo: 泌尿器Care &Cure 25(6): 868-873, 2020.
B-e-1
  1. 大庭 康司郎,酒井 英樹: 各科(外科、婦人科、泌尿器科)における側方リンパ節(骨盤リンパ節)郭清意義と実際 泌尿器癌に対する骨盤内リンパ節郭清の意義と実際. 日本外科系連合学会誌 45(5): 569, 2020.

論文研究業績集計表

論文数一覧
A-a A-b A-c A-d A-e SCI 合計 B-a B-b B-c B-d B-e 合計 総計
2020 18 3 0 0 6 23 27 4 9 0 0 1 14 41
学会発表数一覧
A-a A-b 合計 B-a B-b 合計 総計
ｼﾝﾎﾟｼﾞｳﾑ 学会 ｼﾝﾎﾟｼﾞｳﾑ 学会
2020 0 0 3 3 0 2 34 36 39
論文総数に係る教員生産係数一覧
欧文論文総数論文総数 教員生産係数（欧文論文） SCI掲載論文数欧文論文総数 教員生産係数（SCI掲載論文）
2020 0.659 3.000 0.852 2.556
Impact factor 値一覧
Impact factor 教員当たり Impact factor 論文当たり Impact factor
2020 323.855 35.984 14.081

2019年度　｜　2021年度

Facebookページ

UroUroブログ

長崎大学